Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Department of Pathology, St. Vincent's Hospital, University of Melbourne, Parkville, Victoria, Australia.
Division of Cancer Research, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):385-94. doi: 10.1016/j.ijrobp.2013.10.043.
To examine the effects of combined blockade of DNA-dependent protein kinase (DNA-PK) and poly(adenosine diphosphate-ribose) polymerase-1 (PARP-1) on accelerated senescence in irradiated H460 and A549 non-small cell lung cancer cells.
The effects of KU5788 and AG014699 (inhibitors of DNA-PK and PARP-1, respectively) on clonogenic survival, DNA double-strand breaks (DSBs), apoptosis, mitotic catastrophe, and accelerated senescence in irradiated cells were examined in vitro. For in vivo experiments, H460 xenografts established in athymic nude mice were treated with BEZ235 (a DNA-PK, ATM, and phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor) and AG014699 to determine effects on proliferation, DNA DSBs, and accelerated senescence after radiation.
Compared with either inhibitor alone, combination treatment with KU57788 and AG014699 reduced postradiation clonogenic survival and significantly increased persistence of Gamma-H2AX (γH2AX) foci in irradiated H460 and A549 cells. Notably, these effects coincided with the induction of accelerated senescence in irradiated cells as reflected by positive β-galactosidase staining, G2-M cell-cycle arrest, enlarged and flattened cellular morphology, increased p21 expression, and senescence-associated cytokine secretion. In irradiated H460 xenografts, concurrent therapy with BEZ235 and AG014699 resulted in sustained Gamma-H2AX (γH2AX) staining and prominent β-galactosidase activity.
Combined DNA-PK and PARP-1 blockade increased tumor cell radiosensitivity and enhanced the prosenescent properties of ionizing radiation in vitro and in vivo. These data provide a rationale for further preclinical and clinical testing of this therapeutic combination.
研究联合阻断 DNA 依赖性蛋白激酶(DNA-PK)和聚(腺苷二磷酸核糖)聚合酶-1(PARP-1)对辐射诱导的 H460 和 A549 非小细胞肺癌细胞加速衰老的影响。
在体外研究 KU5788 和 AG014699(分别为 DNA-PK 和 PARP-1 的抑制剂)对辐射细胞克隆存活、DNA 双链断裂(DSB)、细胞凋亡、有丝分裂灾难和加速衰老的影响。对于体内实验,在裸鼠建立 H460 异种移植瘤后,用 BEZ235(一种 DNA-PK、ATM 和磷脂酰肌醇 3-激酶/哺乳动物雷帕霉素靶蛋白抑制剂)和 AG014699 处理,以确定其对辐射后增殖、DNA DSB 和加速衰老的影响。
与单独使用任一抑制剂相比,KU57788 和 AG014699 的联合治疗降低了辐射后 H460 和 A549 细胞的克隆存活能力,并显著增加了照射后γ-H2AX(γH2AX)焦点的持续存在。值得注意的是,这些效应与照射细胞中加速衰老的诱导相一致,表现为β-半乳糖苷酶染色阳性、G2-M 细胞周期阻滞、细胞形态增大和平坦化、p21 表达增加以及衰老相关细胞因子的分泌。在照射的 H460 异种移植瘤中,BEZ235 和 AG014699 的联合治疗导致持续的γ-H2AX(γH2AX)染色和明显的β-半乳糖苷酶活性。
联合阻断 DNA-PK 和 PARP-1 增加了肿瘤细胞的放射敏感性,并增强了体外和体内电离辐射的促衰老特性。这些数据为进一步的临床前和临床测试这种治疗组合提供了依据。